Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

1.160 -0.050 (-4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexicon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Which stocks are gapping on Monday?
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?
Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from its PROGRESS Phase 2b study evaluating pilavapadin. 
Via Benzinga
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Analyst Expectations For Lexicon Pharmaceuticals's Future
 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Confirms Previously Disclosed and Anticipated FDA Decision 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Preview: Lexicon Pharmaceuticals's Earnings
 
Via Benzinga
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
 
Via Benzinga
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
 
Via Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
 
Via Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
 
Via Benzinga
Topics Stocks
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.